Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

September 7, 2023

Study Completion Date

December 1, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Durvalumab

Durvalumab IV (intravenous infusion)

OTHER

Placebo

Placebo IV (intravenous infusion)

DRUG

Cisplatin/ Etoposide

Cisplatin/ Etoposide, as per standard of care

DRUG

Carboplatin/ Paclitaxel

Carboplatin /Paclitaxel, as per standard of care

DRUG

Pemetrexed/ Cisplatin

Pemetrexed / Cisplatin, as per standard of care

DRUG

Pemetrexed/ Carboplatin

Pemetrexed / Carboplatin , as per standard of care

RADIATION

Radiation

5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)

Trial Locations (86)

1015

Research Site, Manila

1083

Research Site, Budapest

1121

Research Site, Budapest

1229

Research Site, Makati

1634

Research Site, City of Taguig

2045

Research Site, Törökbálint

5000

Research Site, Iloilo City

5700

Research Site, Gyula

6000

Research Site, Cebu City

6351

Research Site, Seoul

9024

Research Site, Győr

10000

Research Site, Hanoi

10330

Research Site, Bangkok

10400

Research Site, Bangkok

13013

Research Site, La Libertad

15033

Research Site, Lima

20230

Research Site, Aguascalientes

21280

Research Site, Diyarbakır

28644

Research Site, Chungcheongbuk-do

34030

Research Site, Istanbul

35100

Research Site, Izmir

40002

Research Site, Khon Kaen

44280

Research Site, Guadalajara

48108

Research Site, Busan

50200

Research Site, Mueang

52727

Research Site, Gyeongsangnam-do

90110

Research Site, Hat Yai

94300

Research Site, Orizaba

97134

Research Site, Mérida

100000

Research Site, Hanoi

110063

Research Site, New Delhi

115478

Research Site, Moscow

115533

Research Site, Moscow

122001

Research Site, Gūrgaon

125367

Research Site, Moscow

163045

Research Site, Arkhangelsk

197758

Research Site, Saint Petersburg

344037

Research Site, Rostov-on-Don

388325

Research Site, Karamsad

390007

Research Site, Vadodara

400053

Research Site, Mumbai

422005

Research Site, Nashik

454087

Research Site, Chelyabinsk

560068

Research Site, Bangalore

600035

Research Site, Chennai

644013

Research Site, Omsk

700000

Research Site, Ho Chi Minh City

14048900

Research Site, Ribeirão Preto

14784-400

Research Site, Barretos

81520-060

Research Site, Curitiba

88034-000

Research Site, Florianópolis

60336-045

Research Site, Fortaleza

90035-003

Research Site, Porto Alegre

90610-000

Research Site, Porto Alegre

91350-200

Research Site, Porto Alegre

14021-636

Research Site, Ribeirão Preto

15090-000

Research Site, São José do Rio Preto

01246-000

Research Site, São Paulo

656 53

Research Site, Brno

703 00

Research Site, Ostrava

128 08

Research Site, Prague

113-8603

Research Site, Bunkyō City

812-8582

Research Site, Fukuoka

135-8550

Research Site, Kōtoku

606-8507

Research Site, Kyoto

464-8681

Research Site, Nagoya

589-8511

Research Site, Sayama

980-0873

Research Site, Sendai

241-8515

Research Site, Yokohama

0 3100

Research Site, Mexico City

04700

Research Site, México

L27

Research Site, Lima

LIMA 27

Research Site, Lima

LIMA 34

Research Site, Lima

LIMA 41

Research Site, Lima

Unknown

Research Site, Quezon City

Research Site, Ankara

85-796

Research Site, Bydgoszcz

02-300

Research Site, Elblag

80-952

Research Site, Gdansk

10-228

Research Site, Olsztyn

02-781

Research Site, Warsaw

03080

Research Site, Seoul

05505

Research Site, Seoul

06230

Research Site, Ankara

07059

Research Site, Antalya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY